Millions of intravitreal injections of vascular endothelial growth factor (VEGF) neutralizing proteins are performed each year in the United States as the current mainstay treatment for choroidal neovascularization (CNV) in neovascular age-related macular degeneration (NVAMD) [12,13]. Here, VEGFA is linked to wet macular degeneration.